Literature DB >> 10478702

Combinations in the treatment of hypertension: ACE inhibitors and calcium antagonists.

F H Messerli1.   

Abstract

Hypertension control and management of concomitant pathophysiologic conditions may require use of multiple drugs. However, most studies in hypertensive disease have focused on monotherapy. Therefore, our knowledge of combination therapy in the treatment of hypertension is largely extrapolated from these monotherapy studies. Angiotensin-converting enzyme (ACE) inhibitors and calcium antagonist combinations should be particularly efficacious in reducing hypertensive target organ disease. Both of these drug classes have been shown to reduce complications of hypertensive heart disease and renal disease progression. With regard to hypertensive vascular disease, both ACE inhibitors and calcium antagonists have documented benefits. However, their use together in left ventricular hypertrophy and in patients with coronary heart disease, although promising, must be proved through carefully designed, prospective, randomized trials.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10478702     DOI: 10.1016/s0895-7061(99)00113-2

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  12 in total

Review 1.  Ramipril/felodipine extended-release fixed-dose combination: a review of its use in the management of essential hypertension.

Authors:  Risto S Cvetković; Greg L Plosker
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Effect of processing conditions on degree of hydrolysis, ACE inhibition, and antioxidant activities of protein hydrolysate from Acetes indicus.

Authors:  Vignaesh Dhanabalan; Martin Xavier; Nagalakshmi Kannuchamy; Kurukkan Kunnath Asha; Chongtham Baru Singh; Amjad Balange
Journal:  Environ Sci Pollut Res Int       Date:  2017-07-22       Impact factor: 4.223

Review 3.  Optimal antihypertensive therapy for prevention and treatment of left ventricular hypertrophy.

Authors:  P R Liebson; R D Serry
Journal:  Curr Hypertens Rep       Date:  2000-06       Impact factor: 5.369

4.  Effect of successful hypertension control by manidipine or lisinopril on albuminuria and left ventricular mass in diabetic hypertensive patients with microalbuminuria.

Authors:  Roberto Fogari; Amedeo Mugellini; Annalisa Zoppi; Pierangelo Lazzari; Maurizio Destro; Andrea Rinaldi; Paola Preti
Journal:  Eur J Clin Pharmacol       Date:  2005-07-15       Impact factor: 2.953

Review 5.  Fixed-dose combination enalapril/nitrendipine: a review of its use in mild-to-moderate hypertension.

Authors:  M Asif A Siddiqui; Greg L Plosker
Journal:  Drugs       Date:  2004       Impact factor: 9.546

6.  Effects of the fixed combination of manidipine plus delapril in the treatment of hypertension inadequately controlled by monotherapy with either component: a phase III, multicenter, open-label, clinical trial.

Authors:  Annalisa Zoppi; Amedeo Mugellini; Paola Preti; Andrea Rinaldi; Aldo Celentano; Emma Arezzi; Marco Alberici; Roberto Fogari
Journal:  Curr Ther Res Clin Exp       Date:  2003-07

7.  Optimization of hydrolysis conditions for the production of angiotensin-I converting enzyme-inhibitory peptides and isolation of a novel peptide from lizard fish (Saurida elongata) muscle protein hydrolysate.

Authors:  Shanguang Wu; Jianhua Sun; Zhangfa Tong; Xiongdiao Lan; Zhongxing Zhao; Dankui Liao
Journal:  Mar Drugs       Date:  2012-05-18       Impact factor: 6.085

8.  A Convenient RP-HPLC Method for Assay Bioactivities of Angiotensin I-Converting Enzyme Inhibitory Peptides.

Authors:  Wei Wang; Nan Wang; Yu Zhang; Zheng Cai; Qihe Chen; Guoqing He
Journal:  ISRN Biotechnol       Date:  2012-10-21

Review 9.  Management strategies for patients with hypertension and diabetes: why combination therapy is critical.

Authors:  Sara Giunti; Mark Cooper
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-02       Impact factor: 3.738

Review 10.  Rationale for combination therapy as initial treatment for hypertension.

Authors:  Thomas D Giles
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 Jul-Aug       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.